| Project/Area Number |
22790624
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East |
|---|
Principal Investigator |
MITSUNAGA Shuichi 独立行政法人国立がん研究センター, 臨床開発センター, 研究員 (20466197)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 緩和医療 / 膵がん / 悪液質 / 神経浸潤 / インターロイキン6 / 炎症性サイトカイン / マウスモデル |
|---|
| Research Abstract |
Cancer cachexia is a major cause of death in advanced pancreatic cancer. Anti-cachectic drug concominant with anti-tumor effect is useful in treatment for patients with pancreatic cancer. This study aimed to reveal the target molecule whose inhibition suppresses cachexia and tumor progression in a noble murine model for cachexia of pancreatic cancer. This study clearly showed interleukin-6 is promising target, and murine model of neural invasion using human pancreatic cancer cell is appropriated for the model of cancer cachexia. The inhibition of IL-6 pathways suppressed neural invasion, but it was difficult to confirm the improvement of cancer cachexia in our noble model of cancer cachexia.
|
